Focus:
Central Nervous System
-
18 November 2019 News
Jazz Pharma’s sleepiness drug solriamfetol gets CHMP recommendation
Jazz Pharmaceuticals has secured a positive opinion from a European Medicines Agency (EMA) panel for solriamfetol to improve wakefulness and decrease excessive daytime sleepiness (EDS) in adults with narcolepsy or...
-
15 November 2019 News
Sarepta and StrideBio sign gene therapy development deal
Sarepta Therapeutics has partnered with StrideBio for the development of in-vivo adeno-associated viral (AAV) based therapies for up to eight targets of the central nervous system (CNS) and neuromuscular conditions.
-
13 November 2019 News
US researchers launch neurohub for brain disease therapies
US researchers have launched a research network, Weill Neurohub, to develop treatments for brain and nervous system diseases and disorders.
-
4 November 2019 News
Alzheimer’s drug Oligomannate gets conditional approval in China
Chinese pharmaceutical firm Shanghai Green Valley Pharmaceuticals has secured conditional approval from the country’s regulatory agency for Oligomannate (GV-971) to improve cognitive function in mild to moderate Alzheimer's disease patients.
-
31 October 2019 Analysis
Is growth factor protein the future of Parkinson’s treatment?
A major, multi-year trial of the GDNF protein as a treatment for Parkinson’s disease published its results in February. While the trial did not meet its primary endpoint, other findings...
-
31 October 2019 News
FDA approves Vumerity to treat relapsing forms of MS
The US Food and Drug Administration (FDA) has approved Biogen and Alkermes’ oral drug Vumerity (diroximel fumarate) to treat relapsing forms of multiple sclerosis (MS).
-
30 October 2019 News
AstraZeneca to sell European and Russian rights for Seroquel
AstraZeneca has signed an agreement to divest and license the commercial rights for Seroquel and Seroquel XR in Europe and Russia to German pharmaceutical company Cheplapharm Arzneimittel.
-
23 October 2019 News
Biogen plans to seek FDA approval for Alzheimer’s drug
Biogen and its partner Eisai have announced plans to seek the US Food and Drug Administration (FDA) approval for an investigational drug, aducanumab, to treat early Alzheimer’s disease (AD).
-
8 October 2019 Analysis
The drugs fighting memory loss
Researchers in Toronto have developed an experimental drug that appears to renew the underlying brain impairments causing memory loss, fuelling hopes that a treatment for cognitive decline linked to depression...
-
20 September 2019 Research Reports
Global spinal muscular atrophy market set to reach US$6.6bn in 2028, says GlobalData
Spinal muscular atrophy (SMA) is a group of neurological disorders that cause a loss in muscle movement due to depleting motor neurons and progressive muscle wasting. The disease can be...
Close
Close
Close
Go Top
